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ABSTRACT: Three novel series of 1,2-benzisothiazole derivatives have been developed as inhibitors of carbonic anhydrase 
isoform IX. Compounds 5c and 5j, tested in vitro on the human colon cell line HT-29, blocked the growth of cells cultured 
under chemically-induced hypoxic conditions, displaying a specific activity against cancer cells characterized by CAIX up-
regulation. Moreover, a synergistic activity of 5c with SN38 (the active metabolite of irinotecan) and 5-fluorouracil on cell 
proliferation under hypoxic conditions was demonstrated. 
INTRODUCTION 
Solid tumors represent a major health problem, as their 
prevalence and incidence worldwide is growing at an 
alarming rate. Actually, according to the International 
Agency for Research on Cancer (IARC), 21.4 million new 
cancer cases and 13.2 million cancer related deaths are pre-
dicted throughout the world by 2030.1 Suitable prevention 
measures and high-quality screenings for early-detection 
help to curb the global burden, but these strategies should 
necessarily be complemented by an improvement in can-
cer treatments, to achieve effective and safe clinical proto-
cols for cancer patients. Chemotherapy and radiotherapy 
have been accompanying over time by novel molecularly 
targeted drugs, addressing both oncogenic pathways in 
cancer cells and angiogenic pathways in tumour endothe-
lial cells.2-4 However, despite an initial significant response, 
most of the available compounds still show poor perfor-
mances as the abnormality of the tumor microenviron-
ment impairs their distribution in the tumor tissues, thus 
providing the driving force for drug fecklessness and re-
sistance. Therefore, focusing on the tumor microenviron-
ment stands up as the current imperative strategy to im-
prove the therapeutic efficacy of both the existing and the 
forthcoming anticancer agents.5,6 
Most solid tumors contain hypoxic regions, arising from an 
imbalance between the oxygen demand of rapidly prolifer-
ating cancer cells and the ability of vasculature to meet 
these needs. To adapt to the impaired environment, cancer 
cells modulate their gene expression pattern and the re-
sulting hypoxia-triggered metabolism leads to the exten-
sive production of lactate, protons, and carbon dioxide. Be-
ing incompatible with cell survival and proliferation, these 
acidic metabolites are secreted in the microenvironment 
thanks to a complex pH regulating machinery, which 
maintains suitable cell pH values by ruling transmembrane 
ions flux. 
A key component of this machinery is represented by car-
bonic anhydrase IX (CAIX), a hypoxia-induced zinc-en-
zyme whose active site, facing the extracellular space, cat-
alyzes efficiently the conversion of carbon dioxide to bicar-
bonate ions and protons. While the former are imported 
inside the tumor cell, to modulate intracellular pH values, 
protons remain outside the plasma membrane feeding mi-
croenvironment acidosis. This latter, in turn, contributes 
to tumor progression via multiple effects including up-reg-
ulation of angiogenic factors and proteases, increased in-
vasion and impaired immune functions. Playing a pivotal 
pH-regulating function, CAIX represents a key survival fac-
tor for tumor cells.7-9 Its ectopic expression is strongly as-
sociated with several types of solid tumors and often cor-
related to poor prognosis, due to aggressive growth, malig-
nant progression and poor treatment response of cancer 
cells. Indeed, through an increase in extra-cellular acidosis, 
CAIX confers resistance to anticancer treatments like 
chemotherapy, radiotherapy and the newer molecularly 
targeted compounds. Accordingly, this enzyme represents 
an excellent drug target for an up-to-date cancer therapy 
as its inhibition, ruining distinctive features of tumor mi-
croenvironment, can not only hit cancer cells but also en-
hance the activity of anticancer drugs such as antiangio-
genic compounds.10 
A huge amount of CAIX inhibitors (CAIs) have been de-
scribed throughout years, most of them represented by ar-
omatic/heterocyclic sulfonamide derivatives. In particular, 
those bearing the primary sulfonamide functional group 
turned out to be the most effective ones, thus imposing 
this fragment as the key structural element of CAIs. Actu-
ally, the nitrogen atom of a primary sulfonamide, once in 
its deprotonated form, is able to coordinate the zinc ion in 
 the active site of the enzyme, thus subtracting it from the 
catalytic machinery of CAIX, which becomes inhibited. 
The functional efficacy of this structural fragment is main-
tained even when it is stiffened into small heterocyclic 
cores, like isothiazoles. The pioneering study of Klebe and 
co-workers11 demonstrated the ability of the benzo[d]iso-
thiazol-3(2H)-one-1,1-dioxide (saccharin, I, Chart 1) to in-
hibit efficiently the target CA IX, and additional authors 
confirmed recently this result in differently substituted 
saccharin derivatives (compounds II and III, Chart 1).12,13 
Moving from these outcomes, and considering that the 
benzo[d]isothiazol-3(2H)-one-1,1-dioxide is used as sweet-
ener in the everyday life, hence it is toxicologically safe, this 
scaffold can rightfully be considered a key intriguing inter-
mediate for the obtainment of novel effective and poten-
tially safe CAIX inhibitors. Prompted by this speculation, 
and exploiting our synthetic expertise in the benzo[d]iso-
thiazol-3(2H)-one-1,1-dioxide core,14,15 we designed and 
synthesized three different series of saccharin derivatives 
of general formula IV (Chart 1), to develop as drug candi-
dates for the treatment of solid tumours via CAIX inhibi-
tion. Differently substituted alkyl- and aryl-amido groups 
were inserted in positions 4, 5 and 6 of the heterocyclic 
scaffold, to start investigating their contribution to both 
the efficacy and the selectivity toward different carbonic 
anhydrase isoenzymes of the designed compounds. 
Chart 1. Carbonic Anhydrase Inhibitors 
 
Scheme 1. Synthesis of Benzo[d]isothiazol-3(2H)one-1,1-
dioxide derivatives 4a,b,h, 5b-f,h,j, and 6a-g. 
 
RESULTS AND DISCUSSION 
Chemistry. The target inhibitors, 4a,b,h, 5b-f,h,j and 6a-
g, were synthesized as illustrated in Scheme 1. The starting 
4-, 5-, and 6-aminobenzo[d]isothiazol-3(2H)-one-1,1-diox-
ide derivatives, 1-3, were prepared according to synthetic 
methods previously described by Rose16 and Saary et al.17 
Once obtained, the key intermediates 1-3 afforded the 
aroyl-substituted compounds by treatment with the suita-
ble aryl chloride, in anhydrous toluene and in the presence 
of triethylamine. Derivative 5j, bearing an acetylamino 
substituent on the distal phenyl ring, was synthesized by 
reaction of the amino compound 2 with acetic anhydride, 
at 100 °C. 
CAs inhibitory activity. We started our functional evalu-
ation by testing the synthesized inhibitors, 4a,b,h, 5b-f,h,j 
and 6a-g, for their efficacy against the target human CAIX. 
As reported in Table 1, all the compounds proved to inhibit 
the enzyme exhibiting potency levels in the nanomo-
lar/high nanomolar range. In the 4-substituted sub-series, 
compounds 4a,b,h, the best inhibitory activity resided in 
the benzamido derivatives, 4a,b, as the presence of a bulky 
and stiff biphenyl ring, like in 4h (Ki 1186 nM), determined 
an almost 5-fold reduction of potency with respect to the 
hit, 4a (Ki 223 nM). Moving from the hit, the insertion of 
an electron-withdrawing substituent in position meta of 
the pendant phenyl ring gave rise to a remarkable increase 
in efficacy and compound 4b (Ki 31,2 nM) turned out to be 
the most effective inhibitor of this sub-series. A similar pat-
tern of structure-activity relationships was observed with 
compounds belonging to the 5-substituted sub-series. Ac-
tually, also in this case, the biphenyl-substituted com-
pound, 5h (Ki 231 nM), was less effective than both the ben-
zamido derivatives, 5b-f, and the acetylamino derivative, 
5j. Regarding compounds 5b-f, the insertion of electron-
withdrawing substituents on the distal phenyl ring con-
tributed more favorably to the inhibitory efficacy than the 
presence of electron-donating ones. Compare for example 
5f, bearing a methoxy group in position para (Ki 74 nM), 
with 5d, carrying a fluoro atom in the same position of the 
ring (Ki 27.2 nM). Significantly, among the electron-with-
drawing atoms inserted on the ring, the best result in terms 
of potency was obtained with a fluoro atom, like in 5d. On 
the contrary, replacement of the fluoro atom with a chloro 
one gave rise to a modest reduction in the inhibitory effi-
cacy of the resulting compound. A remarkable activity 
against hCAIX was observed also with compound 5j (Ki 
30.4 nM), characterized by the presence of the small acet-
ylamino substituent. Derivatives belonging to the 6-substi-
tuted sub-series, 6a-g, were generally less active than the 
corresponding regioisomers, 4 and 5. Actually, they all 
showed Ki values in the high nanomolar range, thus reveal-
ing that this particular substitution pattern on the benziso-
thiazole core is the less effective one for a fruitful interac-
tion with the catalytic site of hCAIX. Moving from the pro-
genitor, 6a (ki 220 nM), neither the insertion of electron-
donating groups, like methyl and methoxy (6f,g), nor the 
presence of electron-withdrawing atoms, like fluoro, 
bromo and chloro on the distant phenyl ring (6b-e), con-
tributed significantly to the observed inhibitory activity, as 
6b-g turned out to be either equipotent or even slightly 
less effective than 6a. Also in this subseries, the presence 
of a chloro atom in the para position of the distal ring had 
the most detrimental effect on the functional efficacy, as 
compound 6e raised its activity to the low micromolar 
range.
 Table 1. Inhibitory Activity of Benzo[d]isothiazole Derivatives 4a,b,h, 5b-f,h,j and 6a-g against Human CA Isozymes I, II, 
VII, IX and XII. 
Ki (nM) 
Compound R hCAI hCAII hCAVII hCAIX hCAXII 
4a C6H5 >50000 184 n.t.a 223 910 
4b C6H4-m-Br 8365 593 >50000 31.2 58.9 
4h C6H4-p-C6H5 >50000 910 n.t.a 1186 89.8 
5b C6H4-m-Br 8120 3925 273 31.5 41.4 
5c C6H4-m-Cl 763 589 94.5 67.9 38.7 
5d C6H4-p-F 7697 6880 705 27.2 35.9 
5e C6H4-p-Cl >50000 2300 n.t.a 86.2 78.5 
5f C6H4-p-OCH3 929 790 609 74.0 52.6 
5h C6H4-p-C6H5 >50000 82.9 n.t.a 231 76.8 
5j CH3 8914 1480 >50000 30.4 670 
6a C6H5 >50000 7270 n.t.a 220 9.4 
6b C6H4-m-Br >50000 837 735 665 459 
6c C6H4-m-Cl >50000 6020 534 233 413 
6d C6H4-p-F >50000 908 810 543 537 
6e C6H4-p-Cl >50000 4670 n.t.a 1920 8.7 
6f C6H4-p-OCH3 >50000 6945 n.t.a 205 8.9 
6g C6H4-p-CH3 >50000 411 355 539 804 
Saccharin  18540 5950 10 103 633 
an.t.: not tested. Errors ± 10% (from 3 different assays, data not shown)
Once screened against the target enzyme, all the synthe-
sized compounds were investigated for their selectivity 
against structurally related CA isoforms, namely hCAI, 
hCAII, hCAVII and hCAXII (Table 1). CAs are highly ex-
pressed in a variety of healthy tissues, where they take part 
to many physiological processes including respiration, 
acid-base balance, and ions transport.18 Accordingly, to be 
exploited as a drug candidate, the ideal CAIX inhibitor 
should possess a functional profile as selective as possible 
against the target enzyme, in order to avoid any side effects 
arising from the interaction with multiple CA isozymes in 
different tissues. 
None of the tested compounds showed any relevant inhib-
itory efficacy against hCAI. On the contrary, they all dis-
played diverse activities against isozymes II and VII, alt-
hough remaining preferential inhibitors of hCAIX. In par-
ticular, focusing on the 5-substituted subseries, which 
proved to inhibit the target enzyme better than the 4- and 
6-isomers, the selectivity ratios against the II and VII 
isoforms ranged from 9 to 250 and 1.4 and 26, respectively. 
Significantly, most of the compounds proved to inhibit 
hCAXII, showing Ki values in the nanomolar/low nanomo-
lar range. Even though this specific isozyme is present to a 
large extent in normal tissues, like colon, kidney, rectum, 
esophagus and prostate, its expression is increased in many 
solid, hypoxic tumors.18 Accordingly, its inhibition cannot 
be considered an undesired event as it should, in principle, 
strengthen the antitumor activity resulting from the block 
of CAIX.19 While compounds belonging to the 4-substi-
tuted sub-series showed a moderate inhibitory preference 
for hCAIX, those of the 6-substituted sub-series turned out 
to be generally more effective against isozyme XII rather 
than IX. Derivatives 5b-f,h proved to inhibit equally the 
two enzymes demonstrating that, among all the com-
pounds obtained modifying the benzisothiazole heterocy-
clic core, those distinguished by a 5-substitution pattern 
offer the best guarantee of being effective as anti-tumor 
agents. 
Anti-proliferative activity. Representative examples of 
the benzisothiazole derivatives, 4b, 5c and 5j, chosen 
among those possessing the best inhibitory profile, were 
tested on human colon adenocarcinoma cell line HT-29, to 
investigate their ability to block cell proliferation in the 
presence of CoCl2. This chloride is able to simulate the con-
ditions of hypoxia by inhibiting prolyl hydroxylation of the 
oxygen-dependent degradation domain of HIF-1α and its 
 subsequent interaction with the protein onco-suppressive 
Von Hippel-Lindau, without affecting cell proliferation.20 
After 72-h exposure, tested compounds alone did not sig-
nificantly inhibit the proliferation of HT-29 cells at any 
drug concentrations. On the contrary, the 72-hour expo-
sure of 5c and 5j in combination with CoCl2 significantly 
inhibited, in a concentration-dependent manner, the pro-
liferation of HT-29, with an IC50 of 44.10±8.4 and 
50.97±0.049 µM, respectively (Table 2). 
Table 2. Anti-proliferative activities on HT-29 cancer cells 
of compounds 4b, 5c,j, alone or in combination with CoCl2 
to simulate hypoxia conditions. 
Compound 
IC50 (M) 
w/o CoCl2              with CoCl2 
4b >100 >100 
5c >100 44.10±8.4 
5j >100 50.97±0.049 
 
Moreover, derivative 5c showed a strong synergistic activ-
ity when tested in combination with two well-known 
chemoterapic agents, SN-38 (the active metabolite of iri-
notecan) and 5-FU. The 72-h exposure of HT-29 cells to 
SN-38 and 5-FU, under the same hypoxic conditions, de-
termined an IC50 of 0.029±0.012 µM and 10.95±2.73 µM, re-
spectively. The concurrent combination of 5c with Sn-38 or 
5-FU determined a high synergistic effect (CI<1 and DRI>1) 
for marked antiproliferative activity (>70% of affected 
cells) (Tables 3 and 4). To evaluate the level of interaction 
(synergistic, additive or antagonist) between compound 5c 
and 5-FU or SN38, the method proposed by Chou21 was fol-
lowed. Briefly, synergism or antagonism for 5c plus 5-FU or 
SN38 has been calculated on the basis of the multiple drug-
effect equation, and quantitated by the combination index 
(CI), where CI<1, CI=1 and CI>1 indicate synergism, additive 
effect and antagonism, respectively. Based on the classic 
isobologram, the CI value has been calculated from the fol-
lowing equation (1): 
CI = [(D)1 /(Dx)1] + [(D)2/(Dx)2]        (1) 
As an example, at the 90% inhibition level (see table 3), 
(Dx)1 and (Dx)2 are the concentrations of compound 5c 
and 5-FU or SN-38, respectively, that induce a 90% inhibi-
tion of cell proliferation; (D)1 and (D)2 are the concentra-
tions of compound 5c and 5-FU or SN-38 in combination 
that also inhibits cell proliferation by 90% (isoeffective as 
compared with the single drugs alone). The dose-reduction 
index (DRI, equations (2) and (3)) defines the degree of 
dose reduction that is possible in combination for a given 
degree of effect as compared with the concentration of 
each drug alone: 
(DRI)1=(Dx)1/(D)1         (2) 
(DRI)2 = (Dx)2/(D)2         (3) 
In other words, the DRI represents the theoretical magni-
tude of concentration reduction allowed for each drug 
when given in synergistic combination in vitro to achieve 
the same effect as that obtained with the concentration of 
each single agent. Indeed, in the case of 5-FU or SN-38, it 
could be possible to reduce the concentration of the drug 
in vitro more than 90-fold or 30-fold (see table 4), respec-
tively, when the drug is combined with compound 5c to 
obtain the same 90% level of cytotoxic effects under hy-
poxic conditions. Of course, synergism and related reduc-
tions of drug concentrations is highly desirable for high 
level of inhibition of cell proliferation (>70%) in order to 
obtain a clinical advantage such as the reduction of tumor 
mass or the control of neoplastic disease. 
Table 3. Synergistic activity of 5c and SN-38 or 5-FU asso-
ciation expressed as combination index (CI) values at 70%, 
80% and 90% inhibition of HT-29 cell proliferation under 
hypoxic conditions. 
Affected Cell Fraction 
(%) 
Combination Index (CI) 
5c+SN-38             5c+5-FU 
70% 1.186 0.621 
80% 0.522 0.508 
90% 0.167 0.493 
 
Table 4. Synergistic activity of 5c and SN-38 or 5-FU asso-
ciation expressed as dose reduction index (DRI) values for 
each drug at 70%, 80% and 90% inhibition of HT-29 cell 





Dose Reduction Index (DRI) 
5c+SN-38                      5c+5-FU 
5c SN-38 5c 5-FU 
70% 32.2870 0.866 2.3710 5.0170 
80% 31.9150 2.0390 2.2470 15.8840 
90% 31.3650 7.3950 2.0730 89.9520 
 
CONCLUSIONS 
Thanks to the earliest studies of Klebe and co-workers,11 the 
1,2-benzisothiazole heterocyclic core (saccharin, Chart 1), 
is now considered a privileged scaffold for the obtainment 
of effective and potentially safe inhibitors of the key anti-
cancer target CAIX. 
In this work we presented three novel series of saccharin 
derivatives, bearing suitably substituted alkyl- and aryl-
amido groups in positions 4, 5, or 6 of the nucleus, which 
 demonstrated to inhibit the target protein showing Ki val-
ues in the nanomolar range. The 5-substitution pattern 
turned out to be the most effective one as the resulting 
compounds, besides inhibiting the target hCAIX, proved to 
block efficiently even the enzymatic activity of the corre-
lated isozyme hCAXII, whose expression is increased in 
many solid, hypoxic tumors. 
A preliminary evaluation of selected synthesized com-
pounds on the human cell line HT-29, chosen as an exam-
ple of solid tumor, revealed the promising anti-prolifera-
tive activity of the novel derivatives (Table 2). Significantly, 
compounds 5c and 5j turned out to be active on cells cul-
tured under chemically-induced hypoxic conditions, 
showing IC50 values in the micromolar range. At the same 
time, they left unaltered those under normoxic conditions, 
thus demonstrating a specific activity against cells charac-
terized by CAIX up-regulation. Compound 5c displayed 
also a strong synergistic activity on colon cancer cell pro-
liferation when tested, under hypoxic conditions, in com-
bination with irinotecan and 5-fluorouracil, both widely 
used in the clinical practice to treat colorectal cancer. 
Moreover, a preliminary in vivo pilot study,21 performed on 
nude mice harbouring a HT-29 tumor xenograft, suggested 
the possible safe tolerability profile of compound 5c. In-
deed, administered at the daily dose of 25 mg/kg and 50 
mg/kg i.p., respectively, for 16 days, the compound gave no 
signs of weight loss or evident toxicity at the clinical in-
spection (data not shown). 
The observed selectivity of action, combined with a func-
tional efficacy in the micromolar range and a safe tolera-
bility profile, suggest that these compounds could be safely 
and effectively administered in combination with chemo-
therapeutic and anti-angiogenic agents, used at lower 
doses (as suggested by the DRI), to ruin tumor microenvi-
ronment and guarantee the effectiveness of the conven-
tional anticancer agents. Accordingly, they are worth de-
veloping to obtain novel drug candidates for the combina-
tion treatment of hypoxic solid tumors. 
EXPERIMENTAL SECTION 
Chemistry. Melting points were determined using a 
Reichert Köfler hot-stage apparatus and are uncorrected. 
Routine 1H-NMR spectra were recorded in DMSO-d6 solu-
tion on a Varian Gemini 200 spectrometer operating at 200 
MHz. Evaporation was performed in vacuo (rotary evapo-
rator). Analytical TLCs were carried out on Merck 0.2 mm 
precoated silica gel aluminum sheets (60 F-254). Purity of 
the target inhibitors, 4a,b,h, 5b-f,h,j and 6a-g, was deter-
mined by HPLC analysis, using a Merck Hitachi D-7000 
liquid chromatograph (UV detection at 242 nm) and a Dis-
covery C18 column (250 mm x 4.6 mm, 5 μm, Supelco), with 
a gradient of water and methanol and a flow rate of 1.5 
mL/min. All the compounds showed percent purity values 
≥95%. Acetic anhydride and the suitably substituted aroyl 
chlorides, used to obtain the target inhibitors, were from 
Alfa Aesar, Aldrich and Fluka. The 4-, 5-, and 6-aminosac-
charin, exploited to prepare the target inhibitors, were ob-
tained as reported previously.16,17 
General Procedure for the Synthesis of N-(1,1,3-trioxo-
2,3-dihydrobenzo[d]isothiazol-4- or 5- or 6-yl)ben-
zamides 4a,b,h, 5b-f,h, and 6a-g. A solution of the appro-
priate benzo[d]isothiazole derivative, 1, 2 or 3 (0.100 g, 0.50 
mmol) in anhydrous toluene was added of the suitable 
benzoyl chloride (0.50 mmol) and triethylamine (0.50 
mmol), and refluxed under stirring until the disappearance 
of the starting material (TLC analysis). The crude so ob-
tained was evaporated to dryness, then water was added 
and the resulting compound, separated as a white solid, 
was collected by filtration, purified through crystallization 
from the suitable solvent and characterized with physio-
chemical and spectroscopic data (Supporting Information, 
Tables 1-6). 
N-(1,1-dioxide-3-oxo-2,3-dihydrobenzo[d]isothiazol-5-
yl)acetamide, 5j. A solution of 5-aminobenzo[d]isothia-
zole 2 (0.100 g, 0.50 mmol) and acetic anhydride (0.047 mL, 
0.50 mmol) was heated at T=100 °C under stirring until the 
disappearance of the starting material (TLC analysis). The 
volatiles were then removed in vacuo and the residue was 
diluted with water. The resulting white solid was collected 
by filtration, washed with water, recrystallized from the ap-
propriate solvent and characterized with physio-chemical 
and spectroscopic data (Supporting Information, Tables 3 
and 4). 
Biology. Reagents, proteins, and cell lines. All the CA 
isoforms were recombinant enzymes obtained in-house as 
reported earlier.22,23 Cell culture media McCoy’s 5A, fetal 
bovine serum (FBS), L-glutamine, and antibiotics were 
from Gibco (Gaithersburg, MD, USA). CoCl2 was pur-
chased from Sigma (St. Louis, MO, USA); CoCl2 was dis-
solved in a stock solution of 10 mM in sterile water for cell 
culture. Plastics were supplied by Sarstedt (Verona, Italy). 
CA inhibition assay. An Applied Photophysics stopped-
flow instrument has been used for assaying the CA cata-
lysed CO2 hydration activity.24 Phenol red (at a concentra-
tion of 0.2 mM) has been used as indicator, working at the 
absorbance maximum of 557 nm, with 20 mM Hepes (pH 
7.5) as buffer, and 20 mM Na2SO4 (for maintaining con-
stant the ionic strength), following the initial rates of the 
CA-catalyzed CO2 hydration reaction for a period of 10-100 
s. The CO2 concentrations ranged from 1.7 to 17 mM for the 
determination of the kinetic parameters and inhibition 
constants. For each inhibitor at least six traces of the initial 
5-10% of the reaction have been used for determining the 
initial velocity. The uncatalyzed rates were determined in 
the same manner and subtracted from the total observed 
rates. Stock solutions of inhibitors (0.1 mM) were prepared 
in distilled-deionized water and dilutions up to 0.01 nM 
were done thereafter with the assay buffer. Inhibitor and 
enzyme solutions were preincubated together for 15 min at 
room temperature prior to assay, in order to allow for the 
formation of the E-I complex. The inhibition constants 
 were obtained by non-linear least-squares methods using 
PRISM 3 and the Cheng-Prusoff equation, as reported ear-
lier,25,26 and represent the mean from at least three differ-
ent determinations. Concentration of all the CA isofoms in 
the assay system varied between 7.8 and 13.6 nM. 
Proliferation assay. Test compounds, 4b, 5c and 5j were 
dissolved in a stock solution of 10 mM in 100% dimethyl-
sulfoxide for in vitro studies. DMSO concentration in the 
control’s media was the same used to make up the highest 
concentration of test compounds in growth media for the 
same experiment. In vitro chemosensitivity was tested on 
colorectal cancer HT-29 cell lines. Cells were plated in ster-
ile 24-well plastic plates and treated for 72 h (using 103 
cells/well of cancer cells in 1 ml of medium) with added 4b, 
5c, 5j (range from 100 µM to 0.1 µM), SN-38 or 5-FU (0.001-
50 µM) alone or in combination with 100 μM CoCl2, or ve-
hicle alone or in combination with 100 μM CoCl2. To deter-
mine the effect of CoCl2 alone on HT-29 cell proliferation, 
cells were treated with 100 μM CoCl2 for 72 h.20 The syner-
gistic effect between 5c and SN-38 or 5-FU was calculated 
with the method of Chou 21 based on the multiple drug–
effect equation, and quantitated by the combination index 
(CI) and the dose reduction index (DRI), where CI<1 and 
DRI>1 indicate synergism. At the end of the experiment, 
cells were harvested with trypsin/EDTA, and viable cells 
were quantified using the automatic cell counter ADAM 
MC Digital B (Twin Helix, Milano, Italy). The data are pre-
sented as the percentage of vehicle-treated cells. The con-
centration of drugs that decreased cell count by 50% (IC50) 
compared with controls was calculated by nonlinear fitting 
of experimental data. All experiments were repeated, inde-
pendently, three times with at least nine samples for each 
concentration. 
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